This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ImClone Scandal: A Timeline

NEW YORK ( TheStreet) -- ImClone founder Samuel Waksal is raising money, hoping to launch a biopharmaceutical start-up. But it wasn't so long ago that the biotech entrepreneur was serving seven years behind bars for a series of white collar crimes that also enmeshed friend and domestic doyenne Martha Stewart.

A quick recap: After receiving a tip in December 2001 that the U.S. Food and Drug Administration would reject the application for Erbitux, a colon cancer drug, Waksal tried to sell 80,000 of the company's shares. The day before the FDA's rejection, Waksal's family, close friends, and other big ImClone shareholders -- including Stewart -- sold millions worth of stock. The stock then started to tank, falling into the teens after its December high of around $60.

Six months later, Waksal was arrested on charges that he illegally acted on inside information in attempting to sell ImClone shares -- and that he tipped family members to do the same.

A host of other charges followed, including bank fraud, obstruction of justice, and even tax evasion on $15 million worth of art.

Here, in pictures, is a brief timeline of Waksal and Co.'s less-than-finer moments with ImClone.

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BMY $65.46 0.71%
LLY $73.69 0.34%
MSO $6.46 4.20%
PFE $34.54 1.10%
AAPL $123.09 -0.93%

Markets

DOW 17,686.54 +8.31 0.05%
S&P 500 2,058.85 +2.70 0.13%
NASDAQ 4,881.0770 +17.7150 0.36%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs